Lifecore Biomedical Inc.

Lifecore Biomedical will provide its earnings results for the second quarter and 6 months ended June 30, 2026, and a corporate update. The company reaffirmed its full-year 2026 guidance for revenue of $120 million to $125 million and adjusted EBITDA of $20.5 million to $25 million. Second-quarter revenue was $34.2 million, down 6.2% from $36.4 million a year earlier, while the net loss widened to $6.2 million from $1.1 million. Lifecore added six new programs in the quarter and expects contractually committed fill/finish demand from its largest customer to double beginning in 2027.

Lifecore Biomedical reaffirmed its 2026 revenue guidance of $120 million to $125 million and adjusted EBITDA of $20.5 million to $25 million, even as second-quarter revenue fell 6.2% year over year to $34.2 million and net loss widened to $6.2 million. The company expects contractually committed fill-finish demand from its largest customer to double beginning in 2027 and exceed 2026 levels by more than 200% in 2028. Lifecore added six development programs during the quarter, bringing to 11 the number of programs that could commercialize by the end of 2028, and completed a Japanese regulatory inspection without material issues, potentially expanding market access. Management anticipates stronger second-half results driven by higher aseptic and development revenue, and targets full-year free cash flow of roughly $7 million to $10 million.

Lifecore Biomedical, an under-utilized fill-finish contract drug manufacturing organization, continues to win new business at an impressive rate while the market remains indifferent, according to Laughing Water Capital's second-quarter 2026 investor letter. The firm believes that when these new business wins translate into revenue, the operating leverage will be massive and Lifecore will generate significant cash. Following the quarter's end, the company disclosed that holders of Series A Preferred Stock were redeeming their shares and that it is evaluating strategic alternatives, leading Laughing Water Capital to think a sale of the company is likely in the not-too-distant future. Lifecore Biomedical shares closed at $4.61 on July 14, 2026, with a market capitalization of $172.92 million, and have lost 39.97% over the past 52 weeks.

Lifecore Biomedical announced a new agreement with a global pharmaceutical company to provide technical transfer services for commercial manufacturing of an injectable suspension therapy for neurological disorders. This marks the company's seventh late-stage program agreement secured within the previous seven months and its second such partnership in two weeks. Barrington raised its price target on Lifecore to $6.50 from $6.00 and maintained an Outperform rating, citing the company's expanding clinical development footprint and progress toward long-term strategic objectives.